SequelSEC

Caribou Biosciences, Inc. CRBU

Biological Products, (No Diagnostic Substances) · CIK 0001619856 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$11.16M
Fiscal year ended 2025-12-31
Operating income
-$148.34M
Fiscal year ended 2025-12-31
Free cash flow
-$112.35M
Fiscal year ended 2025-12-31

Caribou Biosciences, Inc. (CRBU) reported revenue of $11.16M and net income of -$148.12M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Caribou Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Caribou Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$11.16M$9.99M$34.48M$13.85M$9.60M$12.36M$5.79M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$148.34M-$166.62M-$116.06M-$106.40M-$66.98M-$36.12M-$34.30M
Net income-$148.12M-$149.10M-$102.07M-$99.42M-$66.92M-$34.31M-$23.43M
Research & development$109.44M$130.15M$112.08M$82.23M$52.26M$34.42M$23.64M
Weighted-average diluted sharesshares 93.39Mshares 90.32Mshares 73.81Mshares 60.80Mshares 31.66MUnavailableUnavailable
Pretax income-$148.68M-$149.11M-$101.88M-$99.35M-$66.60M-$36.13M-$30.97M
Income tax expense-$550.00K-$9.00K$193.00K$70.00K$321.00K-$1.82M-$7.54M
Diluted EPS$-1.59$-1.65$-1.38$-1.64$-2.11UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$37.91M$46.46M$38.46M$38.02M$24.32M$14.06M$16.46M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Caribou Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$12.36M$16.29M$51.16M$58.34M$240.42M$15.95M$41.07M
Total assets$175.37M$313.31M$432.21M$373.76M$442.36M$36.05MUnavailable
Current assets$145.23M$219.38M$338.84M$260.25M$391.19M$24.31MUnavailable
Total liabilities$53.19M$60.36M$63.81M$72.89M$54.53M$18.16MUnavailable
Current liabilities$25.41M$30.65M$28.30M$28.13M$25.83M$12.39MUnavailable
Total equity incl. NCI$122.18M$252.95M$368.40M$300.87M$387.82M-$23.44M$7.46M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$41.32MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$69.00K$265.00K$148.00K$202.00K$1.15M$150.00KUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.78M$2.48M$3.12M$1.15M$3.99M$2.60MUnavailable

Cash flow

Caribou Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$110.99M-$138.20M-$93.29M-$90.97M-$32.52M-$33.22M-$32.01M
Capital expenditures$1.36M$4.88M$11.61M$6.45M$2.12M$317.00K$884.00K
Investing cash flow$102.24M$86.61M-$68.18M-$93.25M-$176.40M$6.36M$27.23M
Financing cash flow$4.82M$16.72M$154.30M$2.13M$433.43M$1.74M$172.00K
Net change in cash-$3.93M-$34.87M-$7.18M-$182.08M$224.51M-$25.12M-$4.60M
Stock-based compensation$12.68M$16.71M$13.75M$11.72M$3.45M$1.00M$1.23M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.64M$3.93M$3.52M$1.62M$984.00K$900.00K$751.00K

Derived

Caribou Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$112.35M-$143.08M-$104.90M-$97.42M-$34.64M-$33.53M-$32.89M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-1329.4%-1667.2%-336.6%-768.2%-697.8%-292.2%-592.7%
FCF margin-1006.8%-1431.7%-304.3%-703.3%-360.9%-271.3%-568.2%
SBC / revenue113.6%167.2%39.9%84.6%35.9%8.1%21.3%
Current ratio5.71x7.16x11.97x9.25x15.15x1.96xUnavailable
Revenue YoY growth11.7%-71.0%148.9%44.3%-22.4%113.6%Unavailable
Net margin-1327.4%-1491.9%-296.1%-717.8%-697.3%-277.6%-404.8%
R&D / revenue980.7%1302.3%325.1%593.7%544.4%278.5%408.3%
CapEx / revenue12.2%48.8%33.7%46.6%22.1%2.6%15.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRBU in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.